Clinical trials: Mature T-cell Lymphoma
Peripheral T Cell Lymphoma
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
This is a single arm, prospective trial to evaluate the efficacy and safety of Chidamide in combination with previous chemotherapy in peripheral T cell lymphoma patients who did not achieve complete response after 3 cycles of…
- Trial name
- NCT02753543
- Testing
- Chidamide
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Ruijin Hospital
Angioimmunoblastic T-cell Lymphoma (AITL)
Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight
To observe the efficacy and safety of the CEP + Dasatinib + Azacitidine as the first-line treatment regimen for patients with Angioimmunoblastic T-cell Lymphoma.
- Trial name
- NCT07046182
- Testing
- CEP + Dasatinib + Azacitidine
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Zhengzhou University
Cutaneous Lymphoma, Cutaneous T-cell Lymphoma
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
The purpose of this study is to determine if vorinostat combined with low-dose total skin electron beam therapy (TSEBT) offers superior clinical benefit (efficacy \& safety) over low-dose TSEBT alone in participants with mycosis…
- Trial name
- NCT01187446
- Testing
- Total skin electron beam therapy (TSEBT), Vorinostat
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Stanford University
Brain and Central Nervous System Tumors, Lymphoma
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT01273090
- Testing
- imetelstat sodium, laboratory biomarker analysis, pharmacological study
- Where
- 23 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Children's Oncology Group
Peripheral T Cell Lymphoma
Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL
This is a phase II open label, two-arm parallel design study of T-CHOP in patients with treatment naïve PTCL. Two doses of tenalisib (400 mg BID and 800 mg BID) will be evaluated in separate groups (Group 1: 400 mg BID and Group…
- Trial name
- NCT05239910
- Testing
- Tenalisib
- Where
- United States
- Sponsor
- Rhizen Pharmaceuticals SA
Extranodal NK-T-Cell Lymphoma
VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)
Open-labeled, multicenter phase II study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation in patients with stage III/IV extranodal…
- Trial name
- VIDL+ASCT (NCT02544425)
- Testing
- Etoposide, Ifosfamide, Dexamethasone
- Where
- 2 sites in South Korea
- Volunteers
- 27 people
- Sponsor
- Samsung Medical Center
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003816
- Testing
- anti-thymocyte globulin, busulfan, carboplatin
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Roswell Park Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
This randomized phase I trial studies the side effects of vaccine therapy in preventing cytomegalovirus (CMV) infection in patients with hematological malignancies undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01588015
- Testing
- tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma (Non-Hodgkin's Lymphoma)
A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy
This study is designed to evaluate the efficacy and safety of reduced-intensity radiotherapy for stage I/II low-risk nasal-type NK/T-cell lymphoma that has achieved complete remission after chemotherapy.
- Trial name
- NCT07628738
- Testing
- reduced-intensity radiotherapy
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Ruijin Hospital
Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
- Trial name
- NCT06547528
- Testing
- ONO-4685
- Where
- 14 sites in Japan
- Volunteers
- 108 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Cutaneous T-cell Lymphoma
Long-term Use of Romidepsin in Patients With CTCL
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of neoplasm of skin-homing T cells that includes Mycosis Fungoid (MF), which is the most common, Sézary syndrome (SS), the leukemia variant of MF, and other variants of…
- Trial name
- NCT02296398
- Testing
- Romidepsin
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Northwestern University
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of EMD 121974 in treating patients with solid tumors or lymphoma. Cilengitide (EMD 121974) may stop the growth of cancer cells by stopping blood flow to the cancer
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00077155
- Testing
- cilengitide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00918333
- Testing
- panobinostat, everolimus, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Mayo Clinic
Lymphoma, Extranodal NK-T-Cell
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.
- Trial name
- NCT06573138
- Testing
- Selinexor, anti-PD-1 antibody plus Golidocitinib
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Lymphoma, Peripheral T Cell Lymphoma
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
This research is being done to evaluate tazemetostat in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as a possible treatment for peripheral T-Cell Lymphoma (PTCL).
- Conditions
- Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma
- Trial name
- NCT06692452
- Testing
- Tazemetostat, Doxorubicin, Vincristine
- Sponsor
- Eric Jacobsen, MD
T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD7 CAR T-cell therapy.
- Trial name
- NCT06925464
- Testing
- CD7 CAR-T cells infusion
- Where
- 4 sites in China
- Volunteers
- 36 people
- Sponsor
- Beijing GoBroad Hospital
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
This phase II trial studies how well cyclophosphamide works in preventing chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01427881
- Testing
- cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Fred Hutchinson Cancer Center
Peripheral T Cell Lymphoma, Progression, Disease
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
This study is to evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria…
- Trial name
- NCT03150602
- Testing
- Pralatrexate
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- Taiwan Mundipharma Pharmaceuticals Ltd.
Chronic Myeloproliferative Disorders, Leukemia
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006379
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.